Breast Cancer Research and Treatment

, Volume 121, Issue 1, pp 101–110

Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial

  • Christian R. Loehberg
  • Sebastian M. Jud
  • Lothar Haeberle
  • Katharina Heusinger
  • Gerhard Dilbat
  • Alexander Hein
  • Claudia Rauh
  • Peter Dall
  • Nadine Rix
  • Sabrina Heinrich
  • Stefan Buchholz
  • Benno Lex
  • Barbara Reichler
  • Boris Adamietz
  • Ruediger Schulz-Wendtland
  • Matthias W. Beckmann
  • Peter A. Fasching
Clinical trial

DOI: 10.1007/s10549-010-0845-8

Cite this article as:
Loehberg, C.R., Jud, S.M., Haeberle, L. et al. Breast Cancer Res Treat (2010) 121: 101. doi:10.1007/s10549-010-0845-8

Abstract

It has been shown in several studies that antihormonal compounds can offer effective prophylactic treatment to prevent breast cancer. In view of the low participation rates in chemoprevention trials, the purpose of this study was to identify the characteristics of women taking part in a population-based mammography screening program who wished to obtain information about the risk of breast cancer and then participate in the the International Breast Cancer Intervention Study II (IBIS-II) trial, a randomized double-blind controlled chemoprevention trial comparing anastrozole with placebo. A paper-based survey was conducted in a population-based mammography screening program in Germany between 2007 and 2009. All women who met the criteria for the mammography screening program were invited to complete a questionnaire. A total of 2,524 women completed the questionnaire, and 17.7% (n = 446) met the eligibility criteria for the IBIS-II trial after risk assessment. The women who wished to receive further information about chemoprevention were significantly younger (P < 0.01) and had significantly more children (P = 0.03) and significantly more relatives with breast cancer (P < 0.001). There were no significant differences between the participants with regard to body mass index or hormone replacement therapy. Normal mammographic findings at screening were the main reason (42%) for declining to participate in the IBIS-II trial or attend risk counseling. The ultimate rate of recruitment to the IBIS-II trial was very low (three women). Offering chemoprevention to women within a mammography screening unit as part of a paper-based survey resulted in low participation rates for both, the survey and the final participation in the IBIS-II trial. More individualized approaches and communication of breast cancer risk at the time of the risk assessment might be helpful to increase the participation and the understanding of chemopreventive approaches.

Keywords

IBIS-II Chemoprevention trial Mammography screening Patient recruitment Breast cancer risk 

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Christian R. Loehberg
    • 1
  • Sebastian M. Jud
    • 1
  • Lothar Haeberle
    • 1
  • Katharina Heusinger
    • 1
  • Gerhard Dilbat
    • 7
  • Alexander Hein
    • 1
  • Claudia Rauh
    • 1
  • Peter Dall
    • 4
  • Nadine Rix
    • 1
  • Sabrina Heinrich
    • 1
  • Stefan Buchholz
    • 5
  • Benno Lex
    • 3
  • Barbara Reichler
    • 6
  • Boris Adamietz
    • 2
  • Ruediger Schulz-Wendtland
    • 2
  • Matthias W. Beckmann
    • 1
  • Peter A. Fasching
    • 8
  1. 1.Department of OB/Gyn, University Breast Center FranconiaUniveristy Hospital ErlangenErlangenGermany
  2. 2.Department of Gynaecological RadiologyUniveristy Hospital ErlangenErlangenGermany
  3. 3.Department of OB/GynHospital BayreuthBayreuthGermany
  4. 4.Department of OB/GynHospital LueneburgLueneburgGermany
  5. 5.Department of OB/GynCaritas-Hospital St.Josef RegensburgRegensburgGermany
  6. 6.Radiology Center ErlangenErlangenGermany
  7. 7.Radiology Center Roth & WeissenburgRothGermany
  8. 8.Division of Hematology and Oncology, Department of Medicine, David Geffen School of MedicineUniversity of California at Los AngelesLos AngelesUSA

Personalised recommendations